LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lexeo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.76+0.12 (+4.55%)
Close on Oct 19, 2026
- Market cap
- $236.33M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Lexeo Therapeutics has not reported a dividend
No dividend per share appears in Lexeo Therapeutics's annual filings since fiscal 2021.